[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-332694-105":59,"doc-detail-332694-en":135},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":128,"head_meta":130,"extra_data":132,"updated_unix":134},105,"en","co-occurrence-of-clear-cell-renal-cell-carcinoma-and-bladder-urothelial-carcinoma-a-case-report-and-literature-review","Co-occurrence of clear cell renal cell carcinoma and bladder urothelial carcinoma - A case report and literature review","","Clear cell renal cell carcinoma (ccRCC) and bladder urothelial carcinoma (bUC) occurring together is rare and has no unified treatment strategy, resulting in poor outcomes. The report presents a 65-year-old male with a smoking history who developed hematuria in July 2021. Imaging showed a right renal tumor and bladder lesions; surgery included transurethral resection of bladder tumor with laparoscopic partial nephrectomy and radical cystectomy, followed by ureteral management. He later developed metastatic disease treated with tislelizumab plus sunitinib and died in January 2023. Literature analysis of 36 patients is summarized.",{"@graph":69,"@context":127},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/co-occurrence-of-clear-cell-renal-cell-carcinoma-and-bladder-urothelial-carcinoma-a-case-report-and-literature-review/332694/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/co-occurrence-of-clear-cell-renal-cell-carcinoma-and-bladder-urothelial-carcinoma-a-case-report-and-literature-review/332694.png","ImageObject",300,407,{"name":92,"@type":93},"Sage","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-27","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",13,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119,123],{"name":110,"@type":111,"acceptedAnswer":112},"Why is the prognosis poor for patients with co-occurrence of ccRCC and bUC?","Question",{"text":113,"@type":114},"The co-occurrence is rare and lacks a unified treatment plan, which contributes to poor prognosis.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"What treatments were given after the initial diagnosis in this case?",{"text":118,"@type":114},"The patient underwent transurethral resection of a bladder tumor, laparoscopic partial nephrectomy, and laparoscopic radical cystectomy with bilateral ureterostomy, followed by periodic ureteral single J tube replacement.",{"name":120,"@type":111,"acceptedAnswer":121},"What systemic therapy was used when metastatic urothelial carcinoma was diagnosed?",{"text":122,"@type":114},"He received tislelizumab (200 mg every 3 weeks) plus sunitinib (50 mg/day in 4-week cycles with a 2-week interval).",{"name":124,"@type":111,"acceptedAnswer":125},"According to the literature review, what factors were linked to high-risk co-occurrence?",{"text":126,"@type":114},"Smoking and male sex were identified as high-risk factors, with a median survival time of 47.5 months.","https://schema.org",{"og:url":83,"og:type":129,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":131,"canonical":83},"index,follow",{"doc_id":133,"site_id":62},332694,1790139142,{"code":4,"msg":5,"data":136},{"doc_id":133,"user_id":137,"nickname":92,"user_avatar":138,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":139,"file_id":140,"file_url":141,"file_type":142,"file_size":143,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":144,"language":145,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":146,"faqs":147,"seo_title":148,"seo_description":67,"update_tm":149,"read_time":150,"preview_page_count":4},687197207057,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","ONCOLOGY LETTERS 29: 21, 2025  \nCo‑occurrence of clear cell renal cell carcinoma and bladder urothelial carcinoma: A case report and literature review  \nSHUO WU 1* , YULIANG ZUO 1* , MEIHONG YE2 , KUAN WANG 1 , XIAOLONG WANG 1 , XUDONG YANG 1 and CHAOMING WANG 1  \n1Department of Urology, Huanghe Sanmenxia Hospital Affiliated to Henan University of Science and Technology, Sanmenxia, Henan 472000, P.R. China; 2Department of Pathology, Huanghe Sanmenxia Hospital Affiliated to Henan University of Science and Technology, Sanmenxia, Henan 472000, P.R. China  \nReceived July 6, 2024; Accepted September 25, 2024  \nDOI: 10. 3892/ol.2024.14768  \nAbstract. The co‑occurrence of clear cell renal cell carcinoma (ccRCC) and bladder urothelial carcinoma (bUC) is rare, and owing to the lack of a unified treatment plan, the prognosis is poor. The present report describes the case of a 65‑year‑old male patient with a history of smoking and no history of malignant tumors who presented with hematuria at the Huanghe Sanmenxia Hospital Affiliated to Henan University of Science and Technology (Sanmenxia, China) in July 2021. Urinary system computed tomography urography revealed aright renal tumor, and cystoscopy revealed intravesical lesions. The patient underwent transurethral resection of a bladder tumor + laparoscopic partial nephrectomy + laparoscopic radical cystectomy and bilateral ureterostomy. Pathological examination revealed right‑sided ccRCC (pT1aN0M0) and high‑grade invasive bUC (pT2N0M0) . After surgery, the patient underwent bilateral ureteral single J tube replacement in the outpatient clinic every 3 months. In September 2022, the patient presented with a mass on the right side of the neck. Further examination revealed a space‑occupying lesion in the lower part of the left kidney and space‑occupying lesions in the neck, axilla, mediastinal lymph nodes and liver. A neck lymph node puncture biopsy suggested UC, and the patient was diagnosed with metastatic UC (T4N0M1) . The patient received tislelizumab (200 mg once every 3 weeks) + sunitinib (50 mg/day, administered for 4 weeks with a 2‑week interval) for a total of 2 months and died of an advanced tumor in January 2023. In addition, the data of 36 patients with ccRCC and bUC  \nCorrespondence to: Dr Chaoming Wang, Department of Urology, Huanghe Sanmenxia Hospital Affiliated to Henan University of Science and Technology, 2 Heping Road, Sanmenxia, Henan 472000, P.R. China  \nE‑mail: [doctorcmwang@163.com](doctorcmwang@163.com)  \n*Contributed equally  \nKey words: clear cell renal cell carcinoma, bladder urothelial carcinoma, multiple primary malignant neoplasms  \nfrom the literature were analyzed for the present report. The results showed that the median age at first onset was 56.5 years (range, 31‑82 years) and the male‑to‑female ratio was 6:1 . Smoking and male sex may be risk factors for this disease, which has a median survival time of 47.5 months. The survival analysis results showed that the pathological stage of bladder cancer may be associated with its prognosis. The present study reviews the potential risks, clinicopathological characteristics and treatment methods of co‑occurrence of clear ccRCC and bUC. In conclusion, the high‑risk factors for the co‑occurrence of ccRCC and bUC were smoking and male sex, and the median survival time was 47.5 months. The pathological stage of bladder cancer may be related to the prognosis.  \nIntroduction  \nRenal carcinoma and bladder cancer are the most common cancer types among the urinary system tumors, and their incidence and mortality rates account for a considerable proportion of the global population with cancer. Statistics on 36 types of cancer in 185 countries and regions around the world in 2022 showed that bladder cancer and kidney cancer ranked 9 and 14th respectively, with incidence rates of 3.1 and 2.2%, respectively (1) . The main subtypes of renal carcinoma include clear cell carcinoma, chromophobe cell carcinoma and papillary carcin","cbCaicNBe0kggILO","https://ap.wps.com/l/cbCaicNBe0kggILO","pdf",7958697,15,"English","# Introduction\n## Epidemiology and risk factors\n## Bladder cancer staging and urothelial carcinoma subtypes\n## Rarity of co-occurrence of ccRCC and bUC\n# Case report\n## Presentation and diagnosis\n## Surgical treatment and postoperative management\n## Recurrence/metastasis and systemic therapy\n## Outcome","[{\"question\":\"Why is the prognosis poor for patients with co-occurrence of ccRCC and bUC?\",\"answer\":\"The co-occurrence is rare and lacks a unified treatment plan, which contributes to poor prognosis.\"},{\"question\":\"What treatments were given after the initial diagnosis in this case?\",\"answer\":\"The patient underwent transurethral resection of a bladder tumor, laparoscopic partial nephrectomy, and laparoscopic radical cystectomy with bilateral ureterostomy, followed by periodic ureteral single J tube replacement.\"},{\"question\":\"What systemic therapy was used when metastatic urothelial carcinoma was diagnosed?\",\"answer\":\"He received tislelizumab (200 mg every 3 weeks) plus sunitinib (50 mg/day in 4-week cycles with a 2-week interval).\"},{\"question\":\"According to the literature review, what factors were linked to high-risk co-occurrence?\",\"answer\":\"Smoking and male sex were identified as high-risk factors, with a median survival time of 47.5 months.\"}]","Co-occurrence of clear cell renal cell carcinoma and bladder urothelial carcinoma - A case report and literature review | PDF",1789999098,38]